EDITAS MEDICINE INC. - COMMON STOCK

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

07 Aug 2024 08:59:49 By NetDania Notify

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

07 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

05 Aug 2024 06:45:15 By NetDania Notify

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

31 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

14 Jun 2024 00:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

14 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

10 May 2024 03:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2024 Results and Business Updates

08 May 2024 04:00:01 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

02 May 2024 04:00:00 By Nasdaq GlobeNewswire

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

01 May 2024 05:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

22 Apr 2024 13:31:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

28 Feb 2024 04:00:01 By Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

21 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

31 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

08 Jan 2024 05:15:00 By Nasdaq GlobeNewswire

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 04:00:00 By Nasdaq GlobeNewswire

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

13 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

11 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

03 Nov 2023 04:00:00 By Nasdaq GlobeNewswire